WJOG18524G: A Single-Arm Phase II Study Evaluating Bemarituzumab Combined With Ramucirumab and Paclitaxel in Fibroblast Growth Factor Receptor 2b (FGFR2b)-Positive Advanced Gastric or Gastroesophageal Junction Cancer (RAINBIRD) [PDF]
ESMO Gastrointestinal OncologyBackground: Fibroblast growth factor receptor 2b (FGFR2)-overexpressing advanced gastric cancer (AGC) is associated with poor prognosis and limited treatment options.
Naoki Takahashi +2 more
exaly +8 more sources
Journal of Pathology: Clinical Research, 2022 Endometrial carcinoma (EC) is the most common gynecological malignancy and fibroblast growth factor receptor 2 (FGFR2) is a frequently dysregulated receptor tyrosine kinase.
Asmerom T Sengal +2 more
exaly +4 more sources
Preclinical Characterization of Bemarituzumab, an Anti-FGFR2b Antibody for the Treatment of Cancer [PDF]
MAbs, 2021 Bemarituzumab (FPA144) is a first-in-class, humanized, afucosylated immunoglobulin G1 monoclonal antibody (mAb) directed against fibroblast growth factor receptor 2b (FGFR2b) with two mechanisms of action against FGFR2b-overexpressing tumors: inhibition ...
Hong Xiang +2 more
exaly +6 more sources
Fgf10/Fgfr2b Signaling in Mammary Gland Development, Homeostasis, and Cancer [PDF]
Frontiers in Cell and Developmental Biology, 2020 Fibroblast growth factor 10 (Fgf10) is a secreted ligand acting via the Fibroblast growth factor receptor 2b (Fgfr2b). Fgf10/Fgfr2b signaling plays important roles both in the epithelium and in the mesenchyme during mammary gland development. Evidence in
Chengshui Chen +2 more
exaly +7 more sources
Frontiers in Cell and Developmental Biology, 2021 Airway branching morphogenesis depends on the intricate orchestration of numerous biological and physical factors connected across different spatial scales.
Saverio Bellusci +2 more
exaly +3 more sources
Pretreatment Claudin-18.2 Expression Predicts Poorer Survival Outcomes in Locally Advanced Gastric Cancer Treated with Perioperative Chemotherapy [PDF]
DiagnosticsBackground/Objectives: Claudin-18.2 (CLDN18.2) has recently emerged as a therapeutic target in gastric cancer; however, its prognostic relevance in the neoadjuvant setting remains insufficiently defined. We evaluated the clinical significance of CLDN18.2
Gürkan Gül +4 more
doaj +2 more sources
CLDN18 and FGFR2 splicing variants are emerging tumor-associated antigens for cancer therapy [PDF]
Frontiers in Molecular MedicineAlternative splicing and alternative promoters generate splicing variants to expand proteomic and transcriptional diversity to orchestrate physiological activities and dictate tumorigenesis.
Masuko Katoh, Masaru Katoh
doaj +2 more sources
Fibroblast Growth Factor-7 and Hair Biology: Bridging Basic Science and Therapeutic Applications [PDF]
Current Issues in Molecular BiologyAlopecia profoundly impacts psychological well-being and quality of life, yet current therapeutic options such as minoxidil and finasteride exhibit limited efficacy. Fibroblast growth factor 7 (FGF-7), also known as keratinocyte growth factor (KGF), is a
Huey-Chun Huang +3 more
doaj +2 more sources
The FGF–FGFR axis as an immune–metabolic rheostat in gastrointestinal inflammation and cancer [PDF]
Frontiers in ImmunologyFibroblast growth factor (FGF)–fibroblast growth factor receptor (FGFR) signaling constitutes a fundamental regulatory network governing epithelial turnover, metabolic homeostasis, and immune modulation across the gastrointestinal tract.
Khamis Salem Saeed Saad +8 more
doaj +2 more sources
Evidence that metformin promotes fibrosis resolution via activating alveolar epithelial stem cells and FGFR2b signaling [PDF]
Acta Pharmaceutica Sinica BIdiopathic pulmonary fibrosis (IPF) is a progressive disease lacking effective therapy. Metformin, an antidiabetic medication, has shown promising therapeutic properties in preclinical fibrosis models; however, its precise cellular targets and associated
Yuqing Lv +15 more
doaj +2 more sources